Its good to see momentum in the development of this drug post the end of the 4th cohort.
Accelerated approval pathway is the goal.
Still risk in this investment. But considering the very low market cap, small SOI and diverse cutting edge tech in the pipeline, the potential reward from here is huge.
Ann: Phase 1B brain cancer clinical trial approved for initiation, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.323M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $26.66K | 8.722M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 72 | 71177716 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 94220096 | 28 |
View Market Depth
| Last trade - 14.10pm 28/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |